]. The author reviewed the potential benefit of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, in patients with familial hypercholesterolemia (FH) and concluded that PCSK9 inhibitors, lowering low-density lipoprotein cholesterol (LDL-C), should drastically reduce the early mortality and morbidity in FH patients. However, to date, the cardiovascular safety of evolocumab remains inconclusive. Thus, we performed a systematic review and meta-analysis of all studies to determine the cardiovascular safety of evolocumab use.
To the Editor
We were interested in the Editorial article written by Evan A. Stein [1] . The author reviewed the potential benefit of a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, alirocumab and evolocumab, in patients with familial hypercholesterolemia (FH) and concluded that PCSK9 inhibitors, lowering low-density lipoprotein cholesterol (LDL-C), should drastically reduce the early mortality and morbidity in FH patients. However, to date, the cardiovascular safety of evolocumab remains inconclusive. Thus, we performed a systematic review and meta-analysis of all studies to determine the cardiovascular safety of evolocumab use.
We conducted a comprehensive search of MEDLINE, MEDLINE In-Process & Other Non-Indexed Citations, EMBASE, Scopus, and the Cochrane Central Register of Controlled Trials from database inception through April 2016. Using the DerSimonian and Laird random effects models, we calculated pooled risk ratios (RRs) with 95 % confidence intervals (95 % CIs). The between-study heterogeneity was quantified using the Q statistic and I 2 . From the results, the pooled analysis demonstrated that evolocumab significantly reduced the risk of cardiovascular events. (RR, 0.53; 95 % CI, 0.38 to 0.74; P < 0.001, I 2 = 0 %, P heterogeneity = 0.498). It has been known that the reduction of LDL-C can reduce cardiovascular events [2] . LDL-C is associated with inflammation and plaque transformation which leads to atherosclerosis. In the MENDEL-2 (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2) trial [3] , evolocumab yielded >50 % LDL-C reductions in adults with hypercholesterolemia compared with placebo or ezetimibe. Similarly, RUTHERFORD-2 trial [4] , evolocumab yielded 60 % LDL-C reductions compared with placebo. In addition, in the Durable Effect of PCSK9 Antibody Compared w i t h P l a c e b o S t u d y ( D E S C A RT E S ) t r i a l [ 5 ] , evolocumab yielded 57 % LDL-C reductions at 52 weeks as compared with placebo.
In conclusion, the results of this meta-analysis showed that evolocumab significantly reduced the risk of cardiovascular events via the mechanism of LDL-C reductions and thereby strengthened the hypothesis of the author. The significance of this meta-analysis is that it shows that in FH patients who cannot tolerate statins, evolocumab is a valuable option for reduction of cardiovascular events.
